MediciNova
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
4275 Executive Sq Ste 300, La Jolla, Cal...Phone Number
(858) 373-1500Website
www.medicinova.comRevenue
<$5 MillionStock Symbol
MNOVIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About MediciNova
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.Explore more
MediciNova Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MediciNova your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once MediciNova has new funding data
Product Launch: Get notified when MediciNova launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if MediciNova had a recent Job posting/layoffs
Check out if MediciNova is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at MediciNova
Check if MediciNova has recently received funding, and reach out quickly before it becomes old news!
MediciNova, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on MediciNova recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined MediciNova as Masked Content
Find 2 more new buyers
Compare Similar Companies to MediciNova
Compare insights from companies similar to MediciNova, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
MediciNova is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MediciNova is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MediciNova.
MediciNova financials insights
Gather financial insights about MediciNova, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2005
Stock Offering
$116.4M
2025
Stock/Share Issuance
$30M
MediciNova Tech Stack
A closer look at the technologies used by MediciNova
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Earnings
MediciNova announced that its current cash position is sufficient to meet ALS and core program data catalysts into the 2028 timeframe.
Earnings, Financial Planning, Business Finance, Finance, Financial Strategy
Project
MediciNova announced that its core ALS program has received orphan drug disease designation and FastTrack designation from the FDA.
Research & Development, Compliance, Pharmaceuticals
Project
MediciNova announced that full enrollment of the MN-001 study in NAFLD/NASH patients with type 2 diabetes is coming soon, and the company is advancing partnering discussions for both core and non-core assets.
Partnership, Research & Development, Business Development, Pharmaceuticals
Earnings
Earnings, Business Finance, Finance, Financial Operations
MediciNova News & Media
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
LA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the target enrollment of 200 patients has been achieved in the SEANOBI-ALS study (Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS ; NCT 06743776) evaluating MN‑166 (ibudilast) in patients with amyotrophic lateral sclerosisMediciNova CEO Provides Shareholder Update
LA JOLLA, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today provides shareholders a corporate update in the following Letter to Stockholders from CEO Yuichi Iwaki, M.D., Ph.D.MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
LA JOLLA, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application that covers the use of ibudilast (MN-166) in combination with an immune checkpoint inhibitor, specifically an anti-PD-1 antibody, for theMediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
LA JOLLA, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of last patient last visit (LPLV) in its Phase 2 clinical trial, MN-001-NATG-202, evaluating MN-001 (tipelukast) for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM).
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MediciNova
Sign Up For FreeTo access detailed company insights
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.... Read More
